Sonoma Pharmaceuticals (SNOA) Reaches New 1-Year Low at $1.05

Sonoma Pharmaceuticals Inc (NASDAQ:SNOA)’s share price hit a new 52-week low on Tuesday . The stock traded as low as $1.05 and last traded at $1.06, with a volume of 500 shares changing hands. The stock had previously closed at $1.17.

SNOA has been the topic of several analyst reports. Benchmark reaffirmed a “speculative buy” rating and set a $3.00 price target on shares of Sonoma Pharmaceuticals in a report on Friday, July 20th. Zacks Investment Research cut shares of Sonoma Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, August 29th. Finally, ValuEngine upgraded shares of Sonoma Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, September 12th.

The stock has a market cap of $7.91 million, a PE ratio of -0.35 and a beta of 1.00. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.27 and a current ratio of 4.02.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last released its quarterly earnings data on Wednesday, August 8th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.09). The company had revenue of $4.37 million for the quarter. Sonoma Pharmaceuticals had a negative net margin of 83.05% and a negative return on equity of 97.88%. As a group, equities analysts expect that Sonoma Pharmaceuticals Inc will post -2 earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Sonoma Pharmaceuticals stock. Renaissance Technologies LLC grew its stake in shares of Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) by 54.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 91,095 shares of the company’s stock after buying an additional 32,180 shares during the period. Renaissance Technologies LLC owned 1.41% of Sonoma Pharmaceuticals worth $226,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 11.32% of the company’s stock.

About Sonoma Pharmaceuticals (NASDAQ:SNOA)

Sonoma Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and markets solutions for the treatment of chronic skin conditions and advanced tissue care in the United States and internationally. The company offers Levicyn, a hypochlorous acid (HOCl) based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the management of new and old scars resulting from surgical procedures and trauma wounds or burns; SebuDerm, a product indicated to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis; and Ceramax, a Lipogrid based skin barrier cream indicated to relieve and manage the burning and itching associated with various skin conditions.

Further Reading: How to Invest in Growth Stocks

Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply